| Immune-checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell–mediated inflammation and immunosuppression W Xu, J Dong, Y Zheng, J Zhou, Y Yuan, HM Ta, HE Miller, M Olson, ... Cancer immunology research 7 (9), 1497-1510, 2019 | 152 | 2019 |
| Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis N Li, W Xu, Y Yuan, N Ayithan, Y Imai, X Wu, H Miller, M Olson, Y Feng, ... Scientific reports 7 (1), 1485, 2017 | 96 | 2017 |
| CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide SV Radhakrishnan, T Luetkens, SD Scherer, P Davis, ER Vander Mause, ... Nature communications 11 (1), 798, 2020 | 83 | 2020 |
| Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion ML Olson, ERV Mause, SV Radhakrishnan, JD Brody, AP Rapoport, ... Leukemia 36 (7), 1943-1946, 2022 | 72 | 2022 |
| Role of immunotherapy in Ewing sarcoma E Morales, M Olson, F Iglesias, S Dahiya, T Luetkens, D Atanackovic Journal for ImmunoTherapy of Cancer 8 (2), 2020 | 66 | 2020 |
| Solution structure of CCL19 and identification of overlapping CCR7 and PSGL-1 binding sites CT Veldkamp, E Kiermaier, SJ Gabel-Eissens, ML Gillitzer, DR Lippner, ... Biochemistry 54 (27), 4163-4166, 2015 | 51 | 2015 |
| The promise of adoptive cellular immunotherapies in hepatocellular carcinoma PG Hendrickson, M Olson, T Luetkens, S Weston, T Han, D Atanackovic, ... Oncoimmunology 9 (1), 1673129, 2020 | 39 | 2020 |
| Effect of three month treatment with the cathepsin-k inhibitor, balicatib, on biochemical markers of bone turnover in postmenopausal women: Evidence for uncoupling of bone … P Papanastasiou, CE Ortmann, M Olson, A Vigneron, U Trechsel Journal of Bone and Mineral Research 21, S59-S59, 2006 | 19 | 2006 |
| Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity ER Vander Mause, JM Baker, KA Dietze, SV Radhakrishnan, T Iraguha, ... Science Translational Medicine 15 (705), eadd7900, 2023 | 18 | 2023 |
| The role of surface molecule CD229 in Multiple Myeloma M Olson, SV Radhakrishnan, T Luetkens, D Atanackovic Clinical Immunology 204, 69-73, 2019 | 17 | 2019 |
| Quantifying requirements for mitochondrial apoptosis in CAR T killing of cancer cells AL Pourzia, ML Olson, SR Bailey, AC Boroughs, A Aryal, J Ryan, ... Cell Death & Disease 14 (4), 267, 2023 | 8 | 2023 |
| Targeting the tumor microenvironment of Ewing sarcoma E Morales, M Olson, F Iglesias, T Luetkens, D Atanackovic Immunotherapy 13 (17), 1439-1451, 2021 | 7 | 2021 |
| Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics F Korell, ML Olson, D Salas-Benito, MB Leick, RC Larson, A Bouffard, ... Science Translational Medicine 16 (750), eadk7640, 2024 | 6 | 2024 |
| Low-affinity CAR T cells exhibit reduced trogocytosis, preventing fratricide and antigen-negative tumor escape while preserving anti-tumor activity ML Olson, ER Vander Mause, SV Radhakrishnan, JD Brody, AP Rapoport, ... bioRxiv, 2021.12. 05.471117, 2021 | 2 | 2021 |
| CD19 loss by CAR T cell mediated trogoctyosis is regulated by CAR affinity M Olson, T Luetkens, D Atanackovic The Journal of Immunology 206 (1_Supplement), 58.03-58.03, 2021 | 2 | 2021 |
| Restricting CAR T Cell Trafficking Expands Targetable Antigen Space EA Morales, KA Dietze, JM Baker, A Wang, SV Avila, F Iglesias, ... bioRxiv, 2024 | 1 | 2024 |
| Chimeric antigen receptor (CAR) T cells overexpressing Bcl-xL increase proliferation and antitumor activity alone and in combination with BH3 mimetics F Korell, M Olson, D Salas-Benito, MB Leick, RC Larson, H Silva, ... Cancer Research 83 (7_Supplement), 4098-4098, 2023 | 1 | 2023 |
| Targeting trogocytosis through cathepsin B inhibition enhances CAR T cell persistence KA Dietze, ML Olson, E Gebru, D Atanackovic, AP Rapoport, T Luetkens Cancer Research 84 (6_Supplement), 43-43, 2024 | | 2024 |
| Trogocytosis-Resistant CAR T Cells Exhibit Increased Persistence and Prevent Antigen Escape KA Dietze, ML Olson, E Gebru, D Atanackovic, AP Rapoport, T Luetkens Blood 142, 3438, 2023 | | 2023 |
| 533 Survival mechanisms common to immunotherapy and drug tolerant persister tumor cells M Davern, B Chan, L Bencsics, JYT Kung, M Yorsz, G Stone, M Olson, ... Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023 | | 2023 |
